Search results

semaglutide (Rybelsus)

For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise: As monotherapy when metformin is considered inappropriate due to intolerance or contraindications In combination with other medicinal products for the treatment of diabetes

semaglutide (Ozempic)

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

semaglutide (Wegovy)

As an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (body mass index [BMI] ≥27 kg/m2).

semaglutide (Wegovy)

As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of• ≥30 kg/m2 (obesity), or• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.

October 2023 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, October 9) published advice on 12 medicines.

January 2019 decisions news release

A medicine used to treat advanced breast cancer has today (Monday 14 January) been accepted by the Scottish Medicines Consortium (SMC) for use in NHSScotland.

June 2026 decisions news release